摘要
目的:探讨干扰素α1b联合苦参碱治疗慢性乙型肝炎(CHB)并肝纤维化的疗效及不良反应。方法:选择80例CHB并肝纤维化患者。随机分入试验组及对照组各40例。试验组病例用干扰素α1b联合苦参碱治疗,对照组仅用干扰素α1b治疗,并于治疗前后检测肝功能、病毒标志物及肝纤维化血清学指标(HA,LN,PCⅢ,IV-C)等。结果:试验组与对照组临床总有效率分别为92%和71%(P<0.05),HBeAg阴转率分别为59%和34%(P<0.05);肝纤维化指标明显下降,试验组治疗前后比较有统计学差异(P<0.01),对照组治疗前后比较,HA和LN差异有统计学意义(P均<0.01),PCⅢⅣ-C差异无统计学意义。试验组与对照组治疗后比较有统计学差异(P<0.01)。结论:干扰素α1b联合苦参碱治疗CHB并肝纤维化患者有协同抗乙肝病毒、抗肝纤维化效应。
Objective: To assess the efficacy and safety of combination of interferon α1b with matrine in the treatment of liver fibrosis in chronic hepatitis B (CHB). Methods :80 patients with liver fibrosis in CHB were equally randomized to give one of two treatments: interferon α1b plus matrine or interferon α1b alone. The efficacy of the therapy was assessed based on the status of liver functions, virus symbols and indexes of fibrosis serology ( HA, LN, PC Ⅲ, Ⅳ-C ) before and after the administration of drugs. Results:Total efficacy rate of bi-therapy and monotherapy was 92% vs. 71% (P 〈 0.05 ). The negative conversion rate of HBeAg was 59% and 34% , respectively (P 〈 0.05 ). The patients experienced less virus symbols after the treatment than before the treatment(P 〈 0.01 ). The patients receiving the mono-therapy showed significant improvements of HA and LN levels(P 〈 0.01 ) but non-significant difference of PCⅢ and Ⅳ-C(P 〈0.01 ) after the treatment. Conclusion: Combination of interferon α1b with matrine offered synergistic effects against the liver fibrosis in CHB.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2007年第4期314-316,共3页
Chinese Journal of New Drugs